Thalassemia intermedia: Revisited

Galanello, 1998, Relationship between genotype and phenotype. Thalassemia intermedia, Ann. N. Y. Acad. Sci., 850, 325, 10.1111/j.1749-6632.1998.tb10489.x Camaschella, 1995, Thalassemia intermedia, Haematologica, 80, 58 Weatherall, 1995, The molecular basis for phenotypic variability of the common thalassaemias, Mol. Med. Today, 1, 15, 10.1016/1357-4310(95)80014-X Camaschella, 1995, Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients, Am. J. Hematol., 48, 82, 10.1002/ajh.2830480203 Camaschella, 1997, Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia, Am. J. Hematol., 55, 83, 10.1002/(SICI)1096-8652(199706)55:2<83::AID-AJH6>3.0.CO;2-Z Sampietro, 1983, The triplicated alpha-gene locus and heterozygous beta thalassaemia: a case of thalassaemia intermedia, Br. J. Haematol., 55, 709, 10.1111/j.1365-2141.1983.tb02854.x Wainscoat, 1987, Thalassaemia intermedia, Blood Rev., 1, 273, 10.1016/0268-960X(87)90029-4 Kattamis, 1982, The clinical phenotype of beta and delta beta thalassemias in Greece, Eur. J. Pediatr., 139, 135, 10.1007/BF00441497 Thein, 2004, Genetic insights into the clinical diversity of beta thalassaemia, Br. J. Haematol., 124, 264, 10.1046/j.1365-2141.2003.04769.x Weatherall, 2001, Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias, Nat. Rev., Genet., 2, 245, 10.1038/35066048 Weatherall, 2001, Thalassemia intermedia: cellular and molecular aspects, J.Hematol., 86, 186 Ho, 1998, Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?, Br. J. Haematol., 100, 70, 10.1046/j.1365-2141.1998.00519.x Rund, 1997, Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype, Am. J. Hematol., 54, 16, 10.1002/(SICI)1096-8652(199701)54:1<16::AID-AJH3>3.0.CO;2-7 Phadke, 2003, Phenotype score to grade the severity of thalassemia intermedia, Indian J. Pediatr., 70, 477, 10.1007/BF02723137 Olivieri, 1999, The beta-thalassemias, N. Engl. J. Med., 341, 99, 10.1056/NEJM199907083410207 Cappellini, 2001, Thalassemia intermedia: clinical aspects and management, Haematologica, 86, 194 Cappellini, 2002, The adult thalassemic patient, Hematol. J., 65 Borgna-Pignatti, 2003, Thalassemia minor, the Gilbert mutation, and the risk of gallstones, Haematologica, 88, 1106 Premawardhena, 2001, Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia, Lancet, 357, 1945, 10.1016/S0140-6736(00)05082-0 Galanello, 2001, Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia, Br. J. Haematol., 115, 926, 10.1046/j.1365-2141.2001.03200.x Chehal, 2003, Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis, Spine, 28, E245, 10.1097/01.BRS.0000067282.47308.4D Castelli, 2004, Intrathoracic masses due to extramedullary hematopoiesis, Am. J. Med. Sci., 328, 299, 10.1097/00000441-200411000-00012 Pantongrag-Brown, 1992, Case report: chronic spinal cord compression from extramedullary haematopoiesis in thalassaemia-MRI findings, Clin. Radiol., 46, 281, 10.1016/S0009-9260(05)80172-2 Issaragrisil, 1981, Spinal cord compression in thalassemia. Report of 12 cases and recommendations for treatment, Arch. Intern. Med., 141, 1033, 10.1001/archinte.141.8.1033 Fucharoen, 1985, Intracranial extramedullary hematopoiesis inducing epilepsy in a patient with beta-thalassemia-hemoglobin E, Arch. Intern Med., 145, 739, 10.1001/archinte.145.4.739 Smith, 1988, Massive hemothorax due to intrathoracic extramedullary hematopoiesis in a patient with thalassemia intermedia, Chest, 94, 658, 10.1378/chest.94.3.658 Saxon, 1998, Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia, Br. J. Haematol., 101, 416, 10.1046/j.1365-2141.1998.00719.x Cario, 2002, Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis, Ann. Hematol., 81, 478, 10.1007/s00277-002-0501-4 Saghafi, 2005, Extramedullary hematopoiesis with spinal cord compression in beta-thalassemia intermedia, Eur. J. Intern. Med., 16, 596, 10.1016/j.ejim.2005.04.010 Karimi, 2005, Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran, J. Pediatr. Hematol. Oncol., 27, 380, 10.1097/01.mph.0000174386.13109.28 Gupta, 1987, RBC survival, zinc deficiency, and efficacy of zinc therapy in sickle cell disease, Birth Defects Orig. Artic. Ser., 23, 477 Dettelbach, 1985, Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication, J. Clin. Pharmacol., 25, 8, 10.1002/j.1552-4604.1985.tb02796.x al Momen, 1991, Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease, Acta Haematol., 86, 46, 10.1159/000204799 Gimmon, 1982, Juvenile leg ulceration in beta-thalassemia major and intermedia, Plast. Reconstr. Surg., 69, 320, 10.1097/00006534-198202000-00023 Taher, 2004, The incidence of thromboembolic events among 8860 patients with thalassemia major and intermedia in the Mediterranean area and Iran, Blood, 104, 985a, 10.1182/blood.V104.11.3623.3623 Eldor, 2002, The hypercoagulable state in thalassemia, Blood, 99, 36, 10.1182/blood.V99.1.36 Cappellini, 2000, Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia, Br. J. Haematol., 111, 467, 10.1046/j.1365-2141.2000.02376.x Taher, 2002, Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?, Hemoglobin, 26, 107, 10.1081/HEM-120005447 Atichartakarn, 2002, Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients, Br. J. Haematol., 118, 893, 10.1046/j.1365-2141.2002.03711.x Eldor, 1991, In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites, Blood, 77, 1749, 10.1182/blood.V77.8.1749.1749 Aessopos, 2001, Cardiac involvement in thalassemia intermedia: a multicenter study, Blood, 97, 3411, 10.1182/blood.V97.11.3411 Atichartakarn, 2003, Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders, Int. J. Hematol., 78, 139, 10.1007/BF02983382 Atichartakarn, 2004, Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient, Blood, 103, 2844, 10.1182/blood-2003-09-3094 Aessopos, 2005, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia, Chest, 127, 1523, 10.1378/chest.127.5.1523 Gharzuddine, 2002, Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation, Eur. J. Echocardiog., 3, 47, 10.1053/euje.2001.0114 Derchi, 2005, Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies, Haematologica, 90, 452 De, 1998, Final height and endocrine function in thalassaemia intermedia, J. Pediatr. Endocrinol. Metab., 11, 965 Savona-Ventura, 1994, Beta-thalassemia syndromes and pregnancy, Obstet. Gynecol. Surv., 49, 129, 10.1097/00006254-199402000-00025 Skordis, 1998, Fertility in female patients with thalassemia, J. Pediatr. Endocrinol. Metab., 11, 935 Karagiorga-Lagana, 1998, Fertility in thalassemia: the Greek experience, J.Pediatr. Endocrinol. Metab., 11, 945 Nassar, 2005, Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns Spanos, 1990, Red cell alloantibodies in patients with thalassemia, Vox Sang., 58, 50, 10.1111/j.1423-0410.1990.tb02055.x Hmida, 1994, Red cell alloantibodies in patients with haemoglobinopathies, Nouv. Rev. Fr. Hematol., 36, 363 Pippard, 1979, Iron absorption and loading in beta-thalassaemia intermedia, Lancet, 2, 819, 10.1016/S0140-6736(79)92175-5 Cossu, 1981, Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia, Eur. J. Pediatr., 137, 267, 10.1007/BF00443255 Brittenham, 1994, Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major, N. Engl. J. Med., 331, 567, 10.1056/NEJM199409013310902 Treadwell, 2001, Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy, Semin. Hematol., 38, 77, 10.1016/S0037-1963(01)90064-2 Mourad, 2003, Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients, Br. J. Haematol., 121, 187, 10.1046/j.1365-2141.2003.04240.x Cappellini, 2005, Overcoming the challenge of patient compliance with iron chelation therapy, Semin. Hematol., 42, S19, 10.1053/j.seminhematol.2005.01.001 Borgna-Pignatti, 2006, Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major, Blood, 107, 3733, 10.1182/blood-2005-07-2933 Pennell, 2006, Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis, Blood, 107, 3738, 10.1182/blood-2005-07-2948 Wu, 2004, Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major, Ann. Hematol., 83, 471, 10.1007/s00277-003-0820-0 Link, 2001, Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture, J. Lab. Clin. Med., 138, 130, 10.1067/mlc.2001.116487 Ceci, 2002, The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients, Br. J. Haematol., 118, 330, 10.1046/j.1365-2141.2002.03554.x Cohen, 2003, Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone, Blood, 102, 1583, 10.1182/blood-2002-10-3280 Richardson, 2002, Deferiprone: greater efficacy at depleting myocardial than hepatic iron?, Lancet, 360, 501, 10.1016/S0140-6736(02)09758-1 2005 Cappellini, 2006, A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia, Blood, 107, 3455, 10.1182/blood-2005-08-3430 Olivieri, 1997, Iron-chelating therapy and the treatment of thalassemia, Blood, 89, 739, 10.1182/blood.V89.3.739 Fiorelli, 1990, Iron metabolism in thalassemia intermedia, Haematologica, 75, 89 Mancosu, 2000, Histological picture of liver disease in thalassemia intermedia, Pathologica, 92, 241 Jensen, 2004, Evaluation of iron overload, Br. J. Haematol., 124, 697, 10.1111/j.1365-2141.2004.04838.x Kushner, 2001, Secondary iron overload, Hematology (Am. Soc. Hematol. Educ. Program), 47, 10.1182/asheducation-2001.1.47 Olivieri, 1992, Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia, Blood, 79, 2741, 10.1182/blood.V79.10.2741.bloodjournal79102741 Piga, 1998, Late effects of bone marrow transplantation for thalassemia, Ann. N. Y. Acad. Sci., 850, 294, 10.1111/j.1749-6632.1998.tb10486.x Apperley, 1993, Bone marrow transplant for the haemoglobinopathies: past, present and future, Bailliere's Clin. Haematol., 6, 299, 10.1016/S0950-3536(05)80074-5 Uckan, 2005, Life-threatening neurological complications after bone marrow transplantation in children, Bone Marrow Transplant., 35, 71, 10.1038/sj.bmt.1704749 Khojasteh, 2002, Bone marrow transplantation for hematological disorders-Shiraz experience, Indian J. Pediatr., 69, 31, 10.1007/BF02723773 Rund, 1995, Advances in the pathophysiology and treatment of thalassemia, Crit. Rev. Oncol. Hematol., 20, 237, 10.1016/1040-8428(95)00162-Z Olivieri, 1996, Reactivation of fetal hemoglobin in patients with beta-thalassemia, Semin. Hematol., 33, 24 Arruda, 1997, Successful use of hydroxyurea in beta-thalassemia major, N. Engl. J. Med., 336, 964, 10.1056/NEJM199703273361318 Bradai, 2003, Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia, Blood, 102, 1529, 10.1182/blood-2003-01-0117 Dixit, 2005, Hydroxyurea in thalassemia intermedia-a promising therapy, Ann. Hematol., 84, 441, 10.1007/s00277-005-1026-4 Perrine, 1993, A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders, N. Engl. J. Med., 328, 81, 10.1056/NEJM199301143280202 Cappellini, 2000, Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study, Blood Cells Mol. Dis., 26, 105, 10.1006/bcmd.2000.0283 Sher, 1995, Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies, N. Engl. J. Med., 332, 1606, 10.1056/NEJM199506153322404 Collins, 1995, Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial, Blood, 85, 43, 10.1182/blood.V85.1.43.bloodjournal85143 Olivieri, 1997, Treatment of thalassaemia major with phenylbutyrate and hydroxyurea, Lancet, 350, 491, 10.1016/S0140-6736(05)63080-2